Latest Allergy Vaccine Companies Update:
Merck Sharp & Dohme (MSD) Acquired Aimmune Therapeutics, gaining access to their peanut allergy vaccine, Palforzia, and strengthening their allergy treatment portfolio.
ALK-Abello Partnered with Regeneron on their investigational IL-4Rα antagonist, REGN1679, to explore its potential in treating severe allergic diseases.
Circassia Pharmaceuticals Received FDA approval for their grass pollen sublingual tablet allergy vaccine, Grazax®, expanding access to this treatment option.
Stallergenes Greer Launched their first sublingual tablet allergy vaccine for ragweed in the US, Oralair® (ambrosia artemisiifolia sublingual allergenic extract), further diversifying their product portfolio.
Immuno Laboratories Developed the Viaskin® Peanut, a next-generation epicutaneous allergy patch for peanut allergies, currently undergoing Phase 3 clinical trials.
LEO Pharma Announced positive Phase 2b results for their investigational peanut allergy patch, Omalizumab, demonstrating potential for future market entry.
List of Allergy Vaccine companies in the market
-
ALK (Denmark)
-
Stallergenes Greer (Switzerland)
-
Allergy Therapeutics (U.K.)
-
HAL Allergy B.V. (Netherlands)
-
HollisterStier Allergy (U.S.)
-
Zhejiang Wolwo Bio-pharmaceutical Co., Ltd (China)
-
LETIPharma (Spain)
-
Dermapharm Holding SE (Germany)